DR. MATTHEW PETER STRACHOVSKY M.D.
Prescription History 1003133612
Ophthalmology in West Islip, NY


Quality Rating: 91.25 out of 100 score

NPI Status: Active since April 23, 2010

Contact Information

360 MONTAUK HWY
WEST ISLIP, NY
ZIP 11795
Phone: (631) 422-1110

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MATTHEW PETER STRACHOVSKY M.D., an active Ophthalmology specialist practicing in West Islip, NY. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 175 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 49 claims alone.


Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 12
30-Day Fills 24.6
Days Supply 704
NY State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills105.3
Peer Average Days Supply3,022
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.3% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $365.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.44

State Avg Cost Per Claim

$70.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Erythromycin

Generic Formulation: Erythromycin BaseSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 166
NY State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills55.9
Peer Average Days Supply938
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $168.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.35

State Avg Cost Per Claim

$19.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Eylea

Generic Formulation: AfliberceptSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
NY State Average Benchmarks
Peer Average Claims67.0
Peer Average 30-Day Fills69.6
Peer Average Days Supply1,983
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.1% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $51,942.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,328.57

State Avg Cost Per Claim

$2,624.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Aflibercept is used to treat certain serious eye conditions (such as wet age-related macular degeneration, diabetic retinopathy/macular edema, macular edema following retinal vein occlusion). This medication can help preserve vision and prevent blindness. Aflibercept belongs to a class of drugs known as growth factor inhibitors. It works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels.

Ketorolac Tromethamine

Generic Formulation: Ketorolac TromethamineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 22
30-Day Fills 28.6
Days Supply 735
NY State Average Benchmarks
Peer Average Claims99.0
Peer Average 30-Day Fills117.5
Peer Average Days Supply2,998
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.8% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $634.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.84

State Avg Cost Per Claim

$26.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.

Therapeutic Applications

This medication is used to temporarily relieve itching eyes caused by seasonal allergies. It is also used to prevent and treat eye swelling due to a certain type of eye surgery (cataract removal). Ketorolac belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). It works by blocking certain natural substances in your body to reduce pain and swelling.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 49
30-Day Fills 125.0
Days Supply 3,741
NY State Average Benchmarks
Peer Average Claims149.0
Peer Average 30-Day Fills254.5
Peer Average Days Supply7,268
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.1% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $941.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.22

State Avg Cost Per Claim

$20.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 215
NY State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills50.4
Peer Average Days Supply814
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.2% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $237.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.52

State Avg Cost Per Claim

$14.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 24
30-Day Fills 29.4
Days Supply 793
NY State Average Benchmarks
Peer Average Claims135.0
Peer Average 30-Day Fills176.5
Peer Average Days Supply4,637
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.2% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $983.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$40.98

State Avg Cost Per Claim

$52.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 19
30-Day Fills 41.7
Days Supply 1,250
NY State Average Benchmarks
Peer Average Claims70.0
Peer Average 30-Day Fills139.2
Peer Average Days Supply4,099
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.9% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $209.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.03

State Avg Cost Per Claim

$38.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MATTHEW PETER STRACHOVSKY M.D. provides transparency into local medical care patterns within West Islip, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.